How To Reduce Five Key Risks In Fill and Finish
Source: Terumo BCT
Optimize your fill and finish process through automation. Some of the common risks for cell therapy manufacturers during this phase include human error, process variability, contamination, product inconsistency, and documentation inaccuracies. Systems such as the Finia® Fill and Finish System, de-risk your process and produce strong, consistent results.
access the Infographic!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
Terumo BCT
This website uses cookies to ensure you get the best experience on our website. Learn more